Celtaxsys is focused on developing new drugs to treat inflammatory diseases. Celtaxsys’ clinical program includes CTX-4430, a first-in-class oral LTA4 Hydrolase inhibitor for treatment of pulmonary inflammation associated with Cystic Fibrosis.
One of the most frequent recessive genetic diseases, affecting 1 in 2,500 individuals. Although the genetic defect in CF causes malfunction in many organs and tissues, it is most often exacerbations and the accompanying inflammatory respiratory distress that results in hospitalization or life threatening events.
Innate Immunity is an ancient protective system that is active from birth and serves as our first line of defense. This system is now known to be important in both promoting and resolving inflammation. Celtaxsys is developing new ways to modulate innate immunity to reduce inflammation and promote resolution.
The neutrophil is one of the most mobile and potentially destructive cells in the body, and neutrophil dysfunction is a key contributor to many inflammatory diseases. Celtaxsys is developing innovative ways to selectively control and correct neutrophil function.
Celtaxsys is a clinical-stage drug discovery and development company focused on novel
therapeutics that treat inflammatory disease by controlling innate immunity.
Our lead drug candidate, CTX-4430, is currently undergoing clinical trials for Cystic Fibrosis